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Abstract
The current pediatric mental health crisis is characterized by staggering rates of depression, anxiety, and suicide. Beyond this, first-line pharmacologic interventions
for depressive and anxiety disorders in children and adolescents produce variable
responses with two in five youths failing to respond. Given the heterogeneity of
treatment response in pediatric depressive and anxiety disorders, pharmacodynamic biomarkers are necessary to develop precision therapeutics by identifying
clear targets to guide treatment. This mini-review summarizes candidate biomarkers and their development in pediatric mental health conditions. A framework for
how these biomarkers may relate to safety, efficacy (e.g., surrogates for clinical endpoints), tolerability or target engagement (i.e., drug action) in children and adolescents is also presented. Taken together, accumulating data suggest that, in children
and adolescents with myriad psychiatric disorders, pharmacodynamic biomarkers
could facilitate developing drugs with well-defined targets in specific populations,
could inform treatment decisions, and hasten patients’ recovery.

I N T RO DU CT ION
The current pediatric mental health crisis is characterized by staggering rates of depression, anxiety, and
suicide—now the second leading cause of death among
children and young adults aged 10–24.1 Whereas inadequate psychiatric resources, disparities in care, and
limited evidence for many pharmacologic treatments
for anxious and depressed youth fuel this crisis, the
stress of a pandemic has further intensified this perilous
situation.2,3

CURRENT APPROACHES
TO DEVELOPING
PSYCHOPHARACOLOGIC
INTERVENTIONS FOR YOUTHS
The kindling for this crisis is a complicated pediatric
clinical trials landscape which created a precarious imbalance between evidence-based treatments and mental
health needs. Few psychotropic medications have US
Food and Drug Administration (FDA)-approval for use in
youths with depressive and anxiety disorders and off-label
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prescribing is the norm.4 Beyond this, antidepressants
with FDA-approvals for depressive and anxiety disorders
(e.g., fluoxetine, escitalopram, and sertraline) produce
variable responses and two in five adolescents fail to respond.5 Clinical trials in children and adolescents with
depressive and anxiety disorders frequently rely on unidimensional measures of overall symptom severity as the
primary outcome. These measures generally use a linear
combination (i.e., average or sum) of measurement across
multiple symptom dimensions, which can be misleading.
Beyond this, and high placebo response rates,6 improvement in some symptoms may be more important for overall improvement than other symptoms, and symptoms
can interact in complex ways. A related concern is that in
certain youths who have “depression” or “anxiety,” experience symptoms driven by exogenous factors—life struggles, adversity, and chronic variable stress—that boost
scores on some measures. Thus, core symptoms may not
drive these symptom ratings; rather, they may be driven
by impairment. Finally, traditional approaches to identifying effective treatments for children and adolescents
with mental health conditions are often mired by joint
significance concerns related to efficacy and tolerability.7
Yet, response (i.e., efficacy) is inherently linked to tolerability and vice versa, but the joint model of both variables
needed to account for their interaction are rare in clinical
psychopharmacologic treatment trials in youths. These
issues complicate the interpretation of these studies and
lead us to abandon potentially effective interventions.
Children and adolescents who are lucky enough to
respond to medication often enjoy functional recovery;
however, response can take months. Delayed response—
which is common for antidepressant medications in
children and adolescents—relates, in part, to pharmacodynamic processes (e.g., activation of second messenger
systems and gene expression). Children, adolescents, and
their families deserve precision therapeutics in pediatric
mental health—an approach that identifies who will respond to what medication, at what dose the first time.

T H E P OT E N TIAL ROLE OF
O BJ ECT I V E B IOM AR K E R S OF
RES P O N S E I N CH ILD AN D
A D O L E S C E NT PSYCH IAT RY
Objective biomarkers of response (i.e., pharmacodynamic
biomarkers) are critical to developing precision therapeutics; they hold the potential to identify clear targets to
guide treatment. These biomarkers may speak to safety,
efficacy (e.g., surrogate for clinical end point or how a patient feels or functions), tolerability, or target engagement
(i.e., drug action).8 Pharmacodynamic biomarkers can be
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leveraged for both drug development and repurposing
(Figure 1); they can be employed to demonstrate quantifiable response and facilitate successful trials through processes, such as sample stratification (e.g., enrichment with
those who demonstrate evidence of target engagement or
pathway modulation), exposure optimization, and dose
finding. For psychotropic medications, pharmacodynamic
biomarkers are urgently needed to identify subgroups that
are more likely to respond (or not respond) and at what
exposure early in drug development (e.g., exposure optimization). This could focus drug development efforts on
a targeted group that is more likely to respond and, at the
same time, identify patients that are less likely to respond
at a given exposure (e.g., due to genetic variability leading to reduced receptor expression) who may benefit from
alternative treatments or dosing schemes or who may
have a distinct disease phenotype. Pharmacodynamic biomarkers that predict clinical outcomes can be used to target treatment and may function similarly to predictive or
prognostic biomarkers.8
Given the heterogeneity of depressive and anxiety
disorders and the common use of self-reported symptom
monitoring, which is complicated by recall bias, pharmacodynamic biomarkers are necessary to advance mental
health therapeutics for children and adolescents. This
mini-review describes how we might qualify pharmacodynamic biomarkers in child and adolescent psychiatry to
(1) aid in drug development and repurposing and (2) to
improve the therapeutic landscape.

DEVELOPING PHARMACODYNAMIC
BIOMARKERS OF RESPONSE
IN CHILD AND ADOLESCENT
PSYCHIATRY
The development of pharmacodynamic biomarkers must
be rigorous to ensure the quality and strength of evidence
supports the context of use. Below, we pose four questions
that must be answered as we develop pharmacodynamic
biomarkers in child and adolescent psychiatry. Examples
from pediatric pharmacodynamic biomarker studies
are used preferentially, when available, to illustrate our
points. However, due to the dearth of pediatric data, examples from adults are also included.

How do you plan to use pharmacodynamic
biomarkers?
First, we must identify the objective of pharmacodynamic biomarker development. Is the pharmacodynamic biomarker intended to support drug approval
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F I G U R E 1 The potential of pharmacodynamic biomarkers to aid in drug development, repurposing, and precision therapeutics in
children and adolescents

or labelling decisions? Will it serve as the primary end
point or surrogate end point (i.e., intended to substitute
for a clinical outcome)? If intended to support regulatory decisions, formal qualification of the pharmacodynamic biomarker should be considered. Biomarker
qualification is a formal, complex and iterative process which requires input from multiple stakeholders
(e.g., sponsors and regulatory agencies). The FDA has
provided guidance for biomarker qualification9 and
various groups have reviews describing the process
of integrating regulatory guidance (e.g., the FDA and
European Medicines Agency [EMA]) into biomarker
development.10
The qualification process may be initiated by an individual, a sponsor, or consortia who then bears the burden
of risk. An investigator may study a pharmacodynamic
biomarker for a single compound, find the data to be
promising, and then generate interest within a consortium for further development with related compounds.
Biomarker qualification leads to a spectrum of outcomes,
from integration in the drug development process to involvement in approval decisions and inclusion in labeling.
Unfortunately, there is yet to be a qualified pharmacodynamic biomarker for mental health treatment.

The use of lactate infusion to probe benzodiazepine
response in CO2-sensitive panic disorder serves as an example of a potential pharmacodynamic biomarker that
stopped short of formal qualification. Table 1 lists this
and other potential pharmacodynamic biomarkers that
require additional study.
If formal qualification is not desired or cannot be
achieved due to limited evidence, an investigator may
seek guidance from the FDA to gain insight or garner support that a promising biomarker warrants continued study
from a regulatory perspective.

What do you expect the biomarker to tell
you?
Answering this question requires determining the “context of use,” which defines what will be detected in the
clinical population of interest and will dictate the type of
studies required to provide adequate evidence. The context of use should be grounded in a biological rationale
that is shared between the mechanism of action of the
drug and pharmacodynamic biomarker. As an example, Javitt et al. recently evaluated functional magnetic

TARGET TO TREATMENT

TABLE 1
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Potential PD biomarkers in pediatric and adolescent psychotropic drug development
Potential context of
use

Potential
pharmacologic probe

PD

Lactate-induced panic attack

Detect anxiolytic drug
effect in CO2-
sensitive panic
disorder

Lactate

•

Vollmer et al. (2015)14

Platelet serotonin transporter
kinetics

Determine treatment-
related effects
on serotonin
transporter
inhibition in
platelets as a proxy
for brain serotonin
transporter
inhibition

Sertraline (children
and adolescents),
Fluvoxamine (adults),
Fluoxetine (adults)

•

Sallee et al. (1998),15
Rausch et al. (2001),16
Rausch et al. (2002),17
Rausch et al. (2005),18

Serotonin receptor binding
detected by PET

Quantify initial
and steady state
treatment-related
effects on serotonin
receptor binding

Nefazodone (adults),
Paroxetine (adults),
Olanzapine (adults)

•

dMCC %BOLDΔ detected by
fMRI with ketamine infusion

Detect glutaminergic
pathway
modulation in
psychotic disorders
to aid in drug
development

Ketamine vs. placebo

•

Cortico-limbic %BOLDΔ
detected by fMRI during
passive-food view

Detect drug response
in adult women
with binge eating
disorder

Lisdexamfetamine vs.
placebo

•

•

Fleck et al. (2019)24

Task-based qEEG

Detect stimulant
response in
pediatric ADHD

Methylphenidate,
dextroamphetamine

•

•

Chabot et al. (1999),25
Song et al. (2005),26
Isiten et al. (2017),27
Ogrim and Kropotov
(2019)28

Amygdala-based whole brain
FC during resting state fMRI

Detect early response
to escitalopram in
adolescents with
generalized anxiety
disorder

Escitalopram vs. placebo

•

Cortico-limbic FC during task-
based fMRI

Detect cortico-
limbic pathway
modulation in high-
risk depressed youth

Omega−3 polyunsaturated
fatty acids (n−3 PUFA)

•

Cortical inhibition and
excitation during TMS

Detect GABAergic
(SICI) and
Glutaminergic
(ICF) pathway
modulation in
adolescents with
major depressive
disorder

Potential biomarker

•

Preda

•

Author (year)

Kapur et al. (1997),19
Kapur et al. (1998),20
Meyer et al. (1999),21
Meyer et al. (2001)22
Javitt et al. (2018)23

Lu et al. (2021)29

•

Li et al. (2021),30
McNamara et al.
(2021)31
Croarkin et al. (2013),32
Lewis et al. (2016),33
Doruk Camsari et al.
(2019)34
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TABLE 1

(Continued)

Potential biomarker

Potential context of
use

Potential
pharmacologic probe

PD

Preda

Author (year)

•

Masuda et al. (2019)35

•

Murphy et al. (2021)36

•

Groeneveld et al.
(2016),37 Sverdlov
et al. (2021)38

Short-interval intracortical
inhibition during TMS

Detect GABAergic
pathway
modulation in
Autism Spectrum

40 Hz ASSR detected by EEG/
MEG

Detect NMDA/
glutaminergic
modulation in
Schizophrenia
(potential use
in depression,
suicidality)

NeuroCart
(drug-sensitive CNS test battery)

Detect blood-
brain barrier
penetration and
neurophysiologic
modulation by
candidate CNS
compounds

Baseline glutamate, Glutamate
+ glutamine concentrations
in ACC, vlPFC detected by
1
H MRS

Determine initial
change in
neurotransmitter
dynamics in
adolescents with
bipolar I disorder

Divalproex

•

•

Strawn et al. (2012)39

Prefrontal NAA concentrations
detected by 1H MRS

Quantify initial
neurotransmitter
dynamics in bipolar
I disorder

Quetiapine (adults),
Olanzapine
(adolescents)

•

•

Adler et al. (2013),40
DelBello et al.
(2006)41

Prefrontal-amygdala FC during
resting state fMRI

Detect treatment-
related connectivity
effects in youth with
bipolar disorder

Lithium, Quetiapine

•

•

Lippard et al. (2021)42

Cortical %BOLDΔ detected by
fMRI during attention task

Detect treatment-
related functional
cortical activity in
children

DHA vs. placebo

•

NMDA antagonist
AV−101 (adults)

McNamara et al. (2010)43

Abbreviations: ACC, anterior cingulate cortex; ADHD, attention deficit hyperactivity disorder; ASSR, auditory steady state response; BOLD, blood-oxygen
level dependent response; CNS, central nervous system; dMCC, dorsal mid cingulate cortex; EEG, electroencephalogram; FC, functional connectivity; fMRI,
functional magnetic resonance imaging; 1H MRS, proton magnetic resonance spectroscopy; ICF, intracortical facilitation; MEG, magnetoencephalogram;
NMDA, N-methyl-D-aspartate; PD, pharmacodynamics; PET, positron emission tomography; Pred, Predictive; qEEG, quantitative electroencephalogram; SICI,
short-interval cortical inhibition; TMS, transcranial magnetic stimulation; vlPFC, ventral lateral prefrontal cortex.
a

Potential pharmacodynamic biomarkers that may also serve as predictive biomarkers based on the purpose of the primary study.

resonance imaging (fMRI) as a pharmacodynamic biomarker of glutaminergic “functional target engagement”
for early phase drug trials (Table 1). Blood oxygen level-
dependent response, thought to be partially dependent
on glutamate release, was detected after ketamine (i.e.,
glutaminergic MOA) and placebo in a prespecified region
(i.e., midcingulate cortex) thus detecting functional target
engagement or, perhaps more precisely, glutaminergic
pathway modulation.

Another example is the use of fMRI to detect reward
response in eating disorders. Frank et al. quantified predictive error reward response in prespecified regions of
interest and demonstrated exaggerated reward response
(i.e., positive predictive error) in restrictive eating disorders and diminished reward response (i.e., negative
predictive error) in those with binge-based eating disorder. Whether this biomarker could detect pharmacodynamic response is yet to be investigated. It is plausible

TARGET TO TREATMENT

that reward system modulation by opioid antagonism
would be detected given both the drug and predictive
error detected by fMRI interface with an opioid reward
mechanism.11
Quantitative electroencephalogram (qEEG) has been
explored as a pharmacodynamic biomarker in pediatric
attention deficit hyperactivity disorder (ADHD) treatment
and appears responsive to stimulant medication (Table 1).
However, controlled studies with a clear and consistent
context of use are lacking. Future studies should identify
the optimal qEEG measure (e.g., theta/beta ratio), connect
the biological rationale of the measure with the medication mechanism of action, and determine a relevant outcome (e.g., identifying methylphenidate vs. amphetamine
responder).

What steps need to be taken to ensure
analytical validity?
In other words, what evidence is needed to ensure the
pharmacodynamic biomarker measures what its intended to measure? The extent of validation will depend,
in part, on the answers to the above questions, particularly the context of use. Mirroring the analytical method
validation process for drugs, elements such as sensitivity, specificity, reproducibility, and reliability should be
considered and intentionally tested. Sources of biological variability (e.g., genetic, metabolomic) should also
be defined and explained, if possible. As an example
of reproducibility and reliability, the study design utilized by Javitt et al. to develop a pharmacodynamic biomarker of glutaminergic target engagement included a
multisite neuroimaging feasibility evaluation. This is
important given multisite trials are inherent in many
drug-development programs and evidence of biomarker
consistency across sites, particularly for neuroimaging,
is necessary.
Additional considerations for qEEG as a pharmacodynamic biomarker include the development and study of
consistent protocols that control conditions such as eye
position (i.e., open or closed), sleep deprivation, number
of electrodes, and task versus resting state.

What are considerations for clinical
validity?
Pharmacodynamic biomarkers may or may not correspond
with a clinical outcome based on the available evidence
or proposed context of use. At a minimum, pharmacodynamic biomarkers should detect target engagement, pathway modulation, or a disease-related change involving
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the drug mechanism of action. A recent randomized
controlled trial of escitalopram in adolescents with generalized anxiety disorder utilized functional connectivity
detected by resting state MRI to show that early functional
connectivity changes (e.g., 2 weeks post-treatment) predicted clinical improvement in anxiety symptoms at 8
weeks (Table 1). If replicated, this biomarker, serving both
pharmacodynamic and predictive purposes, could shave
weeks off the response time for many patients that results
from delays in switching medication later in treatment.
This is particularly important given that randomized controlled trials of adolescents with depression reveal that
early response and early changes in interventions are associated with greater improvement compared to delayed
changes in treatments.12
Taking the above eating disorder example from Frank
et al. a step further, longitudinal studies may be designed
to understand how well fMRI-determined reward response upon acute treatment with reward modulating
medications (e.g., opioid antagonists) predicts remission
or symptom burden.11 Clearly, this work may take years
to establish and better therapeutics are urgently needed.
In the interim, the pharmacodynamic biomarker could
potentially serve as a reasonably likely surrogate end point
for a clinical outcome, meaning it detects an effect that is
expected, but not established to have clinical benefit.8 One
example of work in progress is the identification of synaptic alterations by positron emission tomography (PET).
Evidence suggests that reduced synaptic density throughout the brain may be seen in individuals with major depressive disorder.13 Synaptic alterations may represent a
surrogate for functional deficits and symptoms, but further work is needed to establish the connection. The glutaminergic agent, ketamine, increases synaptogenesis in
a murine model. Whether ketamine produces the same
effect in humans is yet to be determined; however, the development of PET as a biomarker of synaptic alterations
may elucidate mechanisms of action for ketamine’s antidepressive effects and provide a tool for facilitate novel
therapeutic approaches.
For pediatric mental health disorders, identifying the
“gold standard” clinical outcome for which to establish
clinical validity requires multidisciplinary discourse, particularly given our understanding of the limitations of
self-report clinical assessment tools.

CONC LUSION
To combat the pediatric mental health crisis and reduce rates of death and disability that result from ineffective treatment, we must develop better therapeutics
and use existing therapeutics with more precision.
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Pharmacodynamic biomarkers could allow us to reimagine the therapeutic landscape. These biomarkers could
hasten the development of drugs with well-defined targets
in specific populations, inform treatment decisions, and
potentially restore functioning and decrease distress more
quickly. However, developing these pharmacodynamic
biomarkers requires analytic validity and a process that
is mechanistically and clinically informed and carefully
considers the context of use. We have briefly reviewed
potential pharmacodynamic biomarkers and specific considerations to foster thought, facilitate identifying clear
targets, and furthering the development of promising options in child and adolescent psychiatry. The time to act
is now.
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